Nvidia Corp vs Revvity Inc — how do they compare? Nvidia Corp trades at $223.65 (market cap $5.27T), while Revvity Inc trades at $115.69 (market cap $12.91B). The key difference: Nvidia Corp is far larger — about 408.2× Revvity Inc's market cap, and Nvidia Corp pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| NVDA | RVTY | |
|---|---|---|
Market Cap | $5.27T | $12.91B |
Sector | Technology | Technology |
52-Week High | $235.75 | $117.75 |
52-Week Low | $165.17 | $82.26 |
Enterprise Value | $5.20T | $15.23B |
Dividend Yield | 0.46% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $223.09, up 2.54% today, with strong technical momentum as the price approaches resistance near $224. The company demonstrates exceptional fundamental strength with 55.84% net profit margins and 114.29% ROE for 2025, supported by consistent earnings beats. Recent news highlights AI leadership driving revenue growth acceleration, though some articles caution about growth sustainability given the stock's massive run-up.
Outlook remains positive with Wall Street consensus target of $325.86 implying 46% upside, though risks include peak AI spending concerns and increased competition. The stock presents a compelling growth opportunity but requires careful risk management given elevated valuations and technical overbought conditions.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →